Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2005

01-11-2005

Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like Families

Authors: Shiri Dovrat, Arie Figer, Herma H. Fidder, Pavlos Neophytou, Zvi Fireman, Ravit Geva, Jamal Zidan, Dov Flex, Shimon Bar Meir, Eitan Friedman

Published in: Familial Cancer | Issue 4/2005

Login to get access
Metadata
Title
Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like Families
Authors
Shiri Dovrat
Arie Figer
Herma H. Fidder
Pavlos Neophytou
Zvi Fireman
Ravit Geva
Jamal Zidan
Dov Flex
Shimon Bar Meir
Eitan Friedman
Publication date
01-11-2005
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 4/2005
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-005-1255-7

Other articles of this Issue 4/2005

Familial Cancer 4/2005 Go to the issue

Short communication

Lack of Germ-line Mutations at the Specific BRCA1-IRIS Coding Sequence in 114 Spanish High-risk Breast/ovarian Families

OriginalPaper

Long Term Follow-up of HNPCC Gene Mutation Carriers: Compliance with Screening and Satisfaction with Counseling and Screening Procedures

OriginalPaper

Key word Index Volume 4

OriginalPaper

Behavioral and Economic Impact of a Familial History of Cancers

Short communication

Linkage of a Pedigree Drawing Program and Database to a Program for Determining BRCA Mutation Carrier Probability

OriginalPaper

Contents Volume 4
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits